Tradestie Institutional Equity Comparison Engine · Market Close Nov 19, 2026
MOVE vs PMI: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
PMI Captures Overall Composite Edge (48.4 HOLD vs 40.8 SELL), While MOVE Leads 4–1 on Growth & Valuation Pillars
PMI Overall Winner
6-Pillar Tally: MOVE 4 – 1 PMI (1 Tie)
Matrix Metrics: MOVE 4 – 5 PMI
As of Nov 19, 2026, Picard Medical, Inc. (PMI) captures the overall head-to-head institutional edge over Movano Inc. (MOVE) on higher Unified Composite conviction (48.4/100 HOLD vs. 40.8/100 SELL) after splitting the core matrix 5–4 (led by Valuation Multiples), while MOVE wins 4–1 across the 6-pillar growth and valuation breakdown. MOVE trades at $3.51 (N/M Forward P/E, -226.0% operating margin) versus PMI at $6.30 (N/M Forward P/E, -248.1% operating margin).
- Growth vs. Quality Trade-Off: PMI earns the overall head-to-head edge with a stronger Unified Composite Score (48.4/100 HOLD vs. MOVE 40.8/100 SELL) and 54.06β · 134% Vol risk profile, whereas MOVE leads top-line expansion (+6127.5% YoY revenue growth, N/M PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates.
- Technical & Structure Timing Caution: MOVE is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 24.3); meanwhile PMI trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 42.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About MOVE vs PMI
MOVE
Movano Inc. Common Stock
$3.51
-11.14% 1D
Market Cap
$146.2M
TTM Revenue
$16M
Forward P/E
N/M
Beta / 30D Vol
1.66β · 123% Vol
Unified Composite Score
40.8
SELL
Tech 25.0
Fund 44.0
Flow 70.0
Mom 40.0
Weinstein Technical Phase
Markdown · Sell / avoid
PMI
Head-to-Head Winner
Picard Medical, Inc.
$6.30
-2.17% 1D
Market Cap
$17.1M
TTM Revenue
$6.3M
Forward P/E
N/M
Beta / 30D Vol
54.06β · 134% Vol
Unified Composite Score
48.4
HOLD
Tech 39.0
Fund 45.0
Flow 50.0
Mom 50.0
Weinstein Technical Phase
Neutral · Hold
6-Pillar Scorecard Institutional Category Breakdown (MOVE 4 – 1 PMI)
1. Valuation Multiples
PMI
Forward P/E
N/M
N/M
Trailing P/E
N/M
2.9x
PEG Ratio
N/M
N/M
EV / Revenue
8.4x
3.2x
2. Growth & Scale
MOVE
Revenue Growth (YoY)
+6127.5%
+38.6%
Earnings Growth (YoY)
+0.0%
+0.0%
TTM Revenue (USD)
$16M
$6.3M
Market Cap
$146.2M
$17.1M
3. Profitability & Quality
MOVE
Gross Margin
65.1%
18.6%
Operating Margin
-226.0%
-248.1%
Net Profit Margin
-202.2%
0.0%
Return on Equity (ROE)
-66.5%
0.0%
4. Balance Sheet & Cash Flow
MOVE
Cash Generation (TTM)
-$26M EBITDA
-$17M
Cash Flow Margin
N/A
N/A
Net Cash / Leverage
$13M Net Cash
$3.2M Net Debt
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
MOVE
Options Structure Phase
BREAKDOWN
UNCLASSIFIED
Current IV / %ile
N/A (N/A)
N/A (N/A)
Put/Call OI Skew
0.25x (Call-Skewed)
N/A
OBV Trend / Tech Phase
NEUTRAL · Markdown
NEUTRAL · Neutral
6. R&D & Supply-Chain Moat
Tie
OpEx & R&D Intensity
N/A
N/A
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Software - Infrastructure Operator
Medical Devices Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: MOVE (4) vs PMI (5)| Institutional Metric | MOVE | PMI | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $146.2M | $17.1M | MOVE | |
| Trailing P/E Ratio | N/M | 2.9x | PMI | |
| Forward P/E Ratio | N/M | N/M | Tie | |
| Revenue Growth (YoY) | +6127.5% | +38.6% | MOVE | |
| Operating Margin (TTM) | -226.0% | -248.1% | MOVE | |
| Net Profit Margin | -202.2% | 0.0% | PMI | |
| Return on Equity (ROE) | -66.5% | 0.0% | PMI | |
| 52-Week Range Position | 1% ($3–$35) | 34% ($0–$18) | PMI | |
| Beta / 30D Volatility | 1.66β · 123% Vol | 54.06β · 134% Vol | MOVE | |
| Unified Institutional Score | 40.8 / 100 (SELL) | 48.4 / 100 (HOLD) | PMI | |
| Trailing 12M Revenue (USD) | $16M | $6.3M | Scale | |
| Gross Profit Margin (TTM) | 65.1% | 18.6% | Quality | |
| PEG Ratio & EV / Revenue | N/M PEG · 8.4x EV/Rev | N/M PEG · 3.2x EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | -$26M EBITDA ($13M Net Cash) | -$17M ($3.2M Net Debt) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
PMI +23.88 pp
3M Horizon
PMI +156.24 pp
6M Horizon
PMI +3516.07 pp
1Y Horizon
PMI +216.47 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | MOVE Revenue | PMI Revenue | MOVE Op. Margin | PMI Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2024 | $0M | $0M | -2391.1% | -312.3% | PMI |
| FY2025 | $0M | $0M | -3580.4% | -268.4% | PMI |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
MOVE
BREAKDOWN
Current IV
N/A
IV Percentile
N/A
Put/Call OI Skew
0.25x (Call-Skewed)
IV Regime
Unclassified
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
NEUTRAL
Exact MOVE Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
PMI
UNCLASSIFIED
Current IV
N/A
IV Percentile
N/A
Put/Call OI Skew
N/A
IV Regime
Unclassified
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
NEUTRAL
Exact PMI Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
MOVE Moat Profile
Cyclical / Execution-Driven Positioning
Software - Infrastructure Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
PMI Moat Profile
Cyclical / Execution-Driven Positioning
Medical Devices Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
Investor FAQ MOVE vs PMI Key Questions & Quantitative Answers
As of Nov 19, 2026, Picard Medical, Inc. (PMI) captures the overall head-to-head institutional edge over Movano Inc. (MOVE) on higher Unified Composite conviction (48.4/100 HOLD vs. 40.8/100 SELL) after splitting the core matrix 5–4 (led by Valuation Multiples), while MOVE wins 4–1 across the 6-pillar growth and valuation breakdown. MOVE trades at $3.51 (N/M Forward P/E, -226.0% operating margin) versus PMI at $6.30 (N/M Forward P/E, -248.1% operating margin). Growth vs. Quality Trade-Off: PMI earns the overall head-to-head edge with a stronger Unified Composite Score (48.4/100 HOLD vs. MOVE 40.8/100 SELL) and 54.06β · 134% Vol risk profile, whereas MOVE leads top-line expansion (+6127.5% YoY revenue growth, N/M PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: MOVE is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 24.3); meanwhile PMI trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 42.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
MOVE leads the Growth & Scale pillar: MOVE posts +6127.5% YoY revenue growth and +0.0% YoY earnings growth on $16M TTM revenue (65.1% gross margin, -226.0% operating margin), compared with PMI at +38.6% YoY revenue growth and +0.0% YoY earnings growth on $6.3M TTM revenue (18.6% gross margin, -248.1% operating margin). Across the 2-period historical trajectory (FY2024 to FY2025), MOVE cumulative revenue shifted N/A while PMI shifted N/A. In operating R&D and SG&A reinvestment, MOVE deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for PMI.
PMI screens cheaper on headline valuation multiples. MOVE trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 8.4x EV/Revenue (unreported EBITDA margin), whereas PMI trades at N/M Forward P/E, 2.9x Trailing P/E, N/M PEG, and 3.2x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against MOVE (-66.5% ROE) versus PMI (0.0% ROE) capital efficiency.
In options market volatility and institutional positioning, MOVE carries N/A implied volatility (N/A, Unclassified), a 0.25x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.66β · 123% Vol realized risk). By comparison, PMI carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (54.06β · 134% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
PMI vs MOVE · Reverse Pair
MOVE vs DMRA
· Sector Peer
MOVE vs NUWE
· Sector Peer
MOVE vs TGL
· Sector Peer
PMI vs RDN
· Sector Peer
PMI vs MTG
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem